Danco launches Mifiprex in USA

Danco Laboratories says that it has launched the controversial abortiondrug Mifeprex (mifepristone) in the USA, with shipments to physicians beginning November 20. The US Food and Drug Administration finally granted a marketing license for the drug in October, after years of political wrangling that kept it off the market (Marketletter October 9).

Mifepristone will be available for the termination of early pregnancy, defined as 49 days or less from the beginning of the last menstruation, at a dose of 600mg of mifepristone followed by 400mcg of misoprostol, a prostaglandin, two days later.